Gossamer Bio Outlines Regulatory and Financial Plans in Q1 Earnings Call

During its first-quarter 2026 earnings call, Gossamer Bio outlined plans to submit an NDA for seralutinib in pulmonary arterial hypertension by September 2026. The company also highlighted positive clinical data from PROSERA and CT-FRI sub-study, as well as balance sheet improvements through a convertible note exchange.

By MarketBeat Mon, May 18, 2026 at 4:05 PM GMT+3 7 min read · Yahoo Finance · May 18, 2026, 13:05 UTC

Gossamer Bio Outlines Regulatory and Financial Plans in Q1 Earnings Call

Tickers: $GOSS

Topics: balance_sheet biotech pharma regulatory_updates

Read the full article at Yahoo Finance

More World news

Nvidia Names Colette Kress Interim CEO Following Jensen Huang's Resignation Motley Fool · November 12, 2026, 18:26 UTC
Bit Digital Reports Q3 2026 Net Income of $28.5 Million Amid Revenue Decline Motley Fool · November 12, 2026, 18:26 UTC
EZCORP Reports Strong Q4 2026 Results with Significant EBITDA and Revenue Growth Motley Fool · November 12, 2026, 18:16 UTC
Sabre Corp Shares Decline Following Travelport Denial of Merger Speculation Seeking Alpha · November 12, 2026, 18:21 UTC
Lufax Reports Third Quarter 2026 Net Loss Amid Rising Credit Impairment Costs Motley Fool · November 12, 2026, 18:15 UTC
Avantor Reports Return to Organic Revenue Growth in Third Quarter 2026 Motley Fool · November 12, 2026, 18:15 UTC
MGP Ingredients Rebrands to Sempreon and Announces Strategic Shift Toward Ready-to-Drink Products Motley Fool · November 12, 2026, 18:15 UTC
ICON Reports Q3 2026 Revenue of $2 Billion and Accelerating Book-to-Bill Ratio Motley Fool · November 12, 2026, 18:15 UTC
Beachbody (BODi) Reduces Annual Revenue Breakeven to $125 Million Amid Strategic Pivot Motley Fool · November 12, 2026, 18:15 UTC
Standard Nuclear Reports $577.2 Million Contract Backlog and Targets 2027 DOE Authorization Seeking Alpha · November 12, 2026, 18:10 UTC